pre-IPO PHARMA

COMPANY OVERVIEW

HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Inflammatory Disease
  • Metabolic Disorders
  • Neurodegenerative Disease

  • WEBSITE

    https://www.hotspotthera.com


    CAREER WEBSITE

    https://www.hotspotthera.com/careers/


    SOCIAL MEDIA


    INVESTORS

    atlas-venture sofinnova-partners


    PRESS RELEASES


    Sep 27, 2023

    HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting


    Apr 19, 2023

    HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at AACR Annual Meeting 2023


    Apr 11, 2023

    HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B


    Mar 14, 2023

    HotSpot Therapeutics to Present Two Poster Presentations on CBL-B Program at AACR Annual Meeting 2023


    Jan 3, 2023

    HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B


    For More Press Releases


    Google Analytics Alternative